Purple Biotech Statistics

Total Valuation

Purple Biotech has a market cap or net worth of $6.90 million. The enterprise value is -$724,470.

Market Cap	6.90M
Enterprise Value	-724,470

Important Dates

The next estimated earnings date is Friday, August 15, 2025, before market open.

Earnings Date	Aug 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 526.45 million shares outstanding. The number of shares has increased by 63.55% in one year.

Current Share Class	n/a
Shares Outstanding	526.45M
Shares Change (YoY)	+63.55%
Shares Change (QoQ)	+28.32%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	560.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.21
P/TBV Ratio	1.44
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.00.

Current Ratio	2.72
Quick Ratio	2.57
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-430.17

Financial Efficiency

Return on equity (ROE) is -12.40% and return on invested capital (ROIC) is -15.07%.

Return on Equity (ROE)	-12.40%
Return on Assets (ROA)	-12.83%
Return on Invested Capital (ROIC)	-15.07%
Return on Capital Employed (ROCE)	-23.58%
Revenue Per Employee	n/a
Profits Per Employee	-$436,778
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -71.19% in the last 52 weeks. The beta is -0.74, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.74
52-Week Price Change	-71.19%
50-Day Moving Average	2.46
200-Day Moving Average	3.42
Relative Strength Index (RSI)	42.61
Average Volume (20 Days)	26,347

Short Selling Information

Short Interest	147,340
Short Previous Month	165,700
Short % of Shares Out	5.72%
Short % of Float	n/a
Short Ratio (days to cover)	5.14

Income Statement

Revenue	n/a
Gross Profit	-62,000
Operating Income	-7.74M
Pretax Income	18.76M
Net Income	-3.93M
EBITDA	-7.71M
EBIT	-7.74M
Earnings Per Share (EPS)	-$0.01

Full Income Statement

Balance Sheet

The company has $7.09 million in cash and $137,000 in debt, giving a net cash position of $6.95 million or $0.01 per share.

Cash & Cash Equivalents	7.09M
Total Debt	137,000
Net Cash	6.95M
Net Cash Per Share	$0.01
Equity (Book Value)	32.70M
Book Value Per Share	0.06
Working Capital	4.76M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-11.26M
Capital Expenditures	n/a
Free Cash Flow	-11.26M
FCF Per Share	-$0.02

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-63.55%
Shareholder Yield	-63.55%
Earnings Yield	-56.95%
FCF Yield	-163.16%

Analyst Forecast

The average price target for Purple Biotech is $33.00, which is 1,307.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$33.00
Price Target Difference	1,307.25%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 17, 2024. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Sep 17, 2024
Split Type	Reverse
Split Ratio	0.05:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1